Bispecific Antibodies

Bispecific antibodies represent a promising advancement in cancer immunotherapy that simultaneously targets 2 different antigens to enhance immune response against cancer cells; however, their adoption shows significant disparities between well-equipped urban medical centers and underserved rural healthcare settings.

Bispecific antibodies are unique antibody constructs that simultaneously bind 2 antigens, typically targeting an antigen on myeloma cells and a molecule on an immune cell. By using the patient’s immune system to destroy the malignant plasma cells, bispecific antibodies offer a promising treatment to overcome immunosuppression for patients with relapsing/refractory MM (RRMM).⁴

Along with surgery, radiation, chemotherapy, and targeted therapy, immunotherapy has emerged as the fifth pillar of cancer treatment and is revolutionizing cancer treatment across the board.